Long-Term Safety for Lumateperone (ITI-007) in the Treatment of Schizophrenia

被引：0
|
作者：
Vanover, Kimberly [1 ]
Correll, Christoph [1 ]
Weingart, Michal [1 ]
Saillard, Jelena [1 ]
Hossain, Shawn [1 ]
Glass, Steven [1 ]
Kozauer, Susan [1 ]
Satlin, Andrew [1 ]
Davis, Robert [1 ]
机构：
[1] Intracellular Therapies Inc, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2018年 / 43卷
关键词：
Schizophrenia Novel Treatment; Long-Term Safety; Antipsychotic;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
T184
引用
收藏
页码：S328 / S329
页数：2
相关论文
共 50 条
  • [1] THE CLINICAL DEVELOPMENT OF LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA
    Vanover, Kimberly
    Correll, Christoph
    Dmitrienko, Alex
    Glass, Steve
    O'Gorman, Cedric
    Saillard, Jelena
    Weingart, Michal
    Mates, Sharon
    Davis, Robert
    SCHIZOPHRENIA BULLETIN, 2017, 43 : S16 - S16
  • [2] LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY
    Satlin, Andrew
    Durgam, Suresh
    Vanover, Kimberly E.
    Davis, Robert E.
    Huo, Jason
    Mates, Sharon
    Correll, Christoph
    SCHIZOPHRENIA BULLETIN, 2020, 46 : S214 - S214
  • [3] The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review
    Longo, Giulio
    Cicolini, Angelica
    Orsolini, Laura
    Volpe, Umberto
    BRAIN SCIENCES, 2023, 13 (12)
  • [4] Efficacy of Lumateperone (ITI-007) in Depression Symptoms Associated With Schizophrenia
    Satlin, Andrew
    Davis, Robert
    Durgam, Suresh
    Vanover, Kimberly
    Kozauer, Susan
    Huo, Jason
    Mates, Sharon
    McIntyre, Roger
    NEUROPSYCHOPHARMACOLOGY, 2020, 45 (SUPPL 1) : 248 - 249
  • [5] ITI-007, A NEW APPROACH TO THE TREATMENT OF SCHIZOPHRENIA
    Vanover, Kimberly E.
    Davis, Robert E.
    Mates, Sharon
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S21 - S21
  • [6] Lumateperone (ITI-007) in the treatment of bipolar depression: Efficacy across symptoms
    Durgam, Suresh
    Satlin, Andrew
    Vanover, Kimberly E.
    Davis, Robert E.
    Kozauer, Susan G.
    Huo, Jason
    Mates, Sharon
    Calabrese, Joseph
    BIPOLAR DISORDERS, 2020, 22 : 112 - 112
  • [7] Lumateperone (iti-007) in the treatment of bipolar depression: efficacy across symptoms
    Durgam, Suresh
    Davis, Robert E.
    Kozauer, Susan G.
    Saleem, Ameen
    Huo, Jason
    Calabrese, Joseph R.
    BIPOLAR DISORDERS, 2022, 24 : 36 - 36
  • [8] Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Efficacy Across Symptoms
    Durgam, Suresh
    Satlin, Andrew
    Davis, Robert
    Vanover, Kimberly
    Kozauer, Susan
    Huo, Jason
    Mates, Sharon
    Calabrese, Joseph
    NEUROPSYCHOPHARMACOLOGY, 2020, 45 (SUPPL 1) : 230 - 230
  • [9] Clinical Development of ITI-007 for the Treatment of Schizophrenia
    Vanover, Kimberly
    Davis, Robert
    O'Gorman, Cedric
    Saillard, Jelena
    Weingart, Michal
    Mates, Sharon
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S548 - S549
  • [10] LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY
    Vanover, Kimberly
    Dmitrienko, Alex
    Glass, Steven
    Kozauer, Susan
    Saillard, Jelena
    Weingart, Michal
    Satlin, Andrew
    Mates, Sharon
    Correll, Christoph
    Davis, Robert
    SCHIZOPHRENIA BULLETIN, 2018, 44 : S341 - S341
12345